AbbVie stockholders elected all four Class II directors, ratified the auditor, approved executive compensation, but rejected proposals to eliminate supermajority voting and adopt an independent chair at the 2026 Annual Meeting.
Key takeaways
All four Class II directors (Jennifer L. Davis, Melody B. Meyer, Robert A. Michael, Frederick H. Waddell) elected with terms expiring in 2029, each receiving over 93% For votes.
Ernst & Young LLP ratified as independent auditor for 2026 with 98% For votes.
Advisory approval of named executive officer compensation passed with 93% For votes.
Management proposal to amend certificate of incorporation and eliminate supermajority voting failed despite 96% For votes.
Stockholder proposal for independent chair policy rejected with only 39% For votes.